Survey of infectious diseases providers reveals variability in duration of antibiotic therapy for the treatment of Gram-negative bloodstream infections.
Journal
JAC-antimicrobial resistance
ISSN: 2632-1823
Titre abrégé: JAC Antimicrob Resist
Pays: England
ID NLM: 101765283
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
27
12
2021
accepted:
10
01
2022
entrez:
14
2
2022
pubmed:
15
2
2022
medline:
15
2
2022
Statut:
epublish
Résumé
Trials supporting shorter durations of antibiotic therapy for Gram-negative bloodstream infections (GN-BSI) have recently been published. However, adoption of these findings into practice is unclear given limited eligibility criteria and relatively large non-inferiority margins of these studies. To better understand contemporary management of GN-BSI, we conducted an international survey of infectious diseases (ID) specialists. We developed and disseminated an online survey to assess practice patterns involving treatment duration of GN-BSI, including providers from 28 countries. χ In total, 277 ID specialists completed the survey (64% physicians, 31% pharmacists). The median reported duration of antibiotics was 7 days (IQR, 7-10 days) for all GN-BSI sources. Thirty percent of providers typically recommend durations that differ by ≥7 days depending on the source of GN-BSI, and 71% treat ≥10 days for at least one source. In an adjusted model, factors associated with increased duration included intra-abdominal (+1.01 days, 95% CI 0.57-1.45 days; There is extensive heterogeneity in duration of therapy for treating GN-BSI, particularly with respect to source of GN-BSI. Investigations into appropriate treatment durations for different GN-BSI sources are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Trials supporting shorter durations of antibiotic therapy for Gram-negative bloodstream infections (GN-BSI) have recently been published. However, adoption of these findings into practice is unclear given limited eligibility criteria and relatively large non-inferiority margins of these studies. To better understand contemporary management of GN-BSI, we conducted an international survey of infectious diseases (ID) specialists.
METHODS
METHODS
We developed and disseminated an online survey to assess practice patterns involving treatment duration of GN-BSI, including providers from 28 countries. χ
RESULTS
RESULTS
In total, 277 ID specialists completed the survey (64% physicians, 31% pharmacists). The median reported duration of antibiotics was 7 days (IQR, 7-10 days) for all GN-BSI sources. Thirty percent of providers typically recommend durations that differ by ≥7 days depending on the source of GN-BSI, and 71% treat ≥10 days for at least one source. In an adjusted model, factors associated with increased duration included intra-abdominal (+1.01 days, 95% CI 0.57-1.45 days;
CONCLUSIONS
CONCLUSIONS
There is extensive heterogeneity in duration of therapy for treating GN-BSI, particularly with respect to source of GN-BSI. Investigations into appropriate treatment durations for different GN-BSI sources are needed.
Identifiants
pubmed: 35156030
doi: 10.1093/jacamr/dlac005
pii: dlac005
pmc: PMC8827556
doi:
Types de publication
Journal Article
Langues
eng
Pagination
dlac005Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR002554
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI104681
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
Références
Biometrics. 1986 Mar;42(1):121-30
pubmed: 3719049
Pharmacotherapy. 2018 Apr;38(4):476-481
pubmed: 29493791
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 27993852
Eur J Clin Microbiol Infect Dis. 2019 May;38(5):851-857
pubmed: 30680566
Clin Infect Dis. 2020 Dec 15;71(12):3071-3078
pubmed: 31858136
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
Clin Microbiol Infect. 2020 Jul;26(7):904-910
pubmed: 32114010
Clin Infect Dis. 2018 Jan 6;66(2):172-177
pubmed: 29190320
Antimicrob Agents Chemother. 2005 Feb;49(2):760-6
pubmed: 15673761
Am J Epidemiol. 2003 Feb 15;157(4):364-75
pubmed: 12578807
Clin Microbiol Infect. 2022 Apr;28(4):550-557
pubmed: 34508886
Int J Antimicrob Agents. 2018 May;51(5):794-798
pubmed: 29309899
JAMA Intern Med. 2017 Sep 1;177(9):1308-1315
pubmed: 28604925
Open Forum Infect Dis. 2019 Aug 30;7(12):ofz386
pubmed: 33335941
Clin Microbiol Infect. 2020 Jul;26(7):897-903
pubmed: 32006697
Int J Antimicrob Agents. 2021 Dec;58(6):106451
pubmed: 34653617
Infection. 2018 Jun;46(3):333-339
pubmed: 29397537
Annu Rev Public Health. 2009;30:151-74
pubmed: 19705558
Clin Infect Dis. 2019 Sep 13;69(7):1091-1098
pubmed: 30535100
JAMA. 2020 Jun 2;323(21):2160-2169
pubmed: 32484534
Trials. 2020 Jan 15;21(1):92
pubmed: 31941546
Clin Infect Dis. 2018 Jan 6;66(1):11-19
pubmed: 29020202